ly 293111 has been researched along with irinotecan in 1 studies
| Studies (ly 293111) | Trials (ly 293111) | Recent Studies (post-2010) (ly 293111) | Studies (irinotecan) | Trials (irinotecan) | Recent Studies (post-2010) (irinotecan) |
|---|---|---|---|---|---|
| 38 | 9 | 6 | 8,002 | 1,885 | 3,752 |
| Protein | Taxonomy | ly 293111 (IC50) | irinotecan (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 2.7 | |
| Interstitial collagenase | Homo sapiens (human) | 6.06 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 1.556 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 3.171 | |
| Acetylcholinesterase | Homo sapiens (human) | 1.827 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 7.9 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 4.7667 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baetz, T; Brail, LH; de Alwis, DP; Doppler, K; Eisenhauer, E; Fisher, B; Khan, AZ; MacLean, M; Moore, M; Siu, L; Walsh, W; Weitzman, A | 1 |
1 trial(s) available for ly 293111 and irinotecan
| Article | Year |
|---|---|
A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Ontario; Time Factors; Treatment Outcome | 2007 |